Akero is a clinical-stage company founded to develop transformational treatments for patients with serious metabolic diseases marked by high unmet medical need.
We began with an engineered protein called efruxifermin (EFX), which we licensed from Amgen and are developing for treatment of metabolic dysfunction-associated steatohepatitis (MASH). MASH is a serious liver disease caused by metabolic dysregulation. EFX is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body.
Summary: The Sr. Manager/Associate Director of Financial Planning and Analysis will be a key member of the Akero Finance team, supporting...
Job Summary The CTMA is a key member of Clinical Operations and will closely partner with the Senior Clinical Trial Manager...
Job Summary Reporting to the VP Clinical Development, the Director, Clinical Development will contribute to the execution of the Phase 3...
Summary: We are seeking an experienced and detail-oriented contract specialist to assist with contract lifecycle management. The contract specialist will collaborate...
Share
Facebook
X
LinkedIn
Telegram
Tumblr
Whatsapp
VK
Mail